# NCT02853331 (NCT02853331)

> Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02853331
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Renal Cell Carcinoma
- Interventions: Pembrolizumab; Axitinib; Sunitinib
- Enrollment: 861
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review
- Primary outcome: Overall Survival (OS)

## Commentary we found

- Podcasts: 38
- X threads: 35
- YouTube: 27

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02853331

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02853331", "email": "<work email>"}; the inbox owner confirms by the emailed link.